US-based Thermo Fisher Scientific, the world’s largest life sciences tools company, has expanded its research and development (R&D) footprint in India with a ₹160 crore investment in its Bengaluru Centre of Excellence. The newly inaugurated 37,000 sq. ft. facility will advance antibody design, development, and manufacturing. It integrates cutting-edge automation and analytical platforms to support immunoassays, protein analysis, and cell-based studies. This expansion is set to create over 100 high-skilled jobs in the coming years.
A Testament to Long-Term Commitment
“This expansion reflects our long-term commitment to India’s innovation ecosystem,” said Gianluca Pettiti, Executive Vice President and Sector President, Life Sciences, Diagnostics and Applied Sector at Thermo Fisher Scientific. “By investing in talent and capabilities here, we will accelerate scientific progress and better serve customers in India and across the world,” he added.
Bengaluru’s Two-Decade Legacy in R&D
Thermo Fisher’s Bengaluru site has been an integral part of the company’s global R&D network for nearly two decades. The centre has developed over 2,000 recombinant antibodies and validated more than 25,000, contributing to key advancements in infectious diseases, cancer biology, and antiviral research. Its manufacturing capabilities have supplied thousands of primary and secondary antibodies to researchers worldwide, strengthening Thermo Fisher’s global leadership in life sciences.
Empowering India’s Life Sciences Ecosystem
“This expansion reinforces our belief in India’s potential to lead in life sciences innovation,” said Manoj Prasad, Vice President, IT & Digital Solutions, APAC & MEA. “With this new infrastructure and infusion of talent, we can accelerate discovery and strengthen our global research network,” he noted.




















